Orthocell Ltd has released a press release.
Part 1 Remplir US Market Authorisation Successfully Complete
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Appendix 4D & Half-Year Financial Statements
- Strategic Placement to Raise $3.5 million
- Remplir Expansion Continues with Singapore Application
- Successful OrthoATI clinical trial
- UWA Royalty Entitlement Exchanged for Shares in Orthocell
Later from Orthocell
- Orthocell receives $3.05m R&D tax incentive refund
- Outstanding 98.6% Success Rate in Striate Implant Study
- Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study
- Third Revenue Generating Product to be Launched in SmrtGraft
- Record Quarterly and Yearly Revenue Show Outstanding Growth
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell